|
7 documents found matching dt:report-marketing.
|
|
Prev
Next
|
|
|
|
Showing 1-7 of 7 documents
|
1.
Overview of 1996 Strategies
|
Document Date:
|
19960000/e
|
|
Search Terms in Context:
|
w
OVERVIEW OF 1996 STRATEGIES
ACCUPRIL
STRATEGY: SPECIALTY MARKETING
AFRICAN AMERICAN - HISPANIC - ELDERLY INITIATIVES
Beginning in January of 1996 (completed in eary May) The Southeast CBU conducted 16 medical
education programs that reached over 700 high decile physicians. As an extension of 1995 proggrams.
which averaged a 58% increase in TMOTS (for attending physicians), the curriculum
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/kib00a10
|
|
| |
2.
Neurontin 1997 Situation Analysis
|
Document Date:
|
19960524
|
|
Search Terms in Context:
|
received a
nonapprovable letter due to issues with safety and case report forms. Perceptions among
neurologists are that Sabril is more potent than the other new AEDs. Regardless of its
substantial clinical experience, sales in Europe are not growing and the incidence of
psychosis is a concern. Sabril's final approval is expected by the end of y1996.
Topamax (Ortho-McNeiI) fNFIfl JT1 A I
Topamax
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/cib00a10
|
|
| |
3.
South Central CBU 1997 Situation Analysis
|
Document Date:
|
19960531
|
|
Search Terms in Context:
|
Story - Does not detract from primary detail
Weakness:
* No 750mg
* Majority of key target physicians not willing to call in patients to be switched
* GPO pricing procedure started too late - resulting in delays and confusion
* Precision Marketing data is questionable
* Delay in approval resulted in rush to launch (fragmented)
* Difficult to switch a generic patient to Procanbid
Opportunities
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/dib00a10
|
|
| |
4.
Northeast CBU 1997 Situation Analysis, 05/31/96
|
Document Date:
|
19960531
|
|
Search Terms in Context:
|
. The first part, is to focus on
our best prescription writers defile 7 - 10. The second part, of our objective is to identify a
new geriatric segment for sales growth.
Strength to Objective
- Conducting interactive consultant meetings.
- Precision marketing
- Utilizing the best medical faculty with Cognex
- Promote AFC
V058084
pgNbr=3
CONFIDENTIAL
Cognex
Marketing Overview
As the leader
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/kdb00a10
|
|
| |
5.
Situation Analysis for Neurontin
|
Document Date:
|
19960612
|
|
Corporate Author:
|
Parke-Davis
|
|
Search Terms in Context:
|
pgNbr=1
PARKE-DAV1S
People Who Care
To: See Attached Distribution List
From: Epilepsy Marketing Team Subject: Situation Analysis for Neurontin
Date: June 12, 1996
cc:
Please replace the Neurontin Situation Analysis that you received on June 6th with the attached. Thank you.
MEMO
W 002190
pgNbr=2
Parke-Davis Management Team G. Cavic
S. Cunningham
R. Dean D. Green J. Howard A. Jerris R. Oliva
L
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/eib00a10
|
|
| |
6.
Parke-Davis - 1998 Marketing Plan: Neurontin
|
Document Date:
|
19980000/e
|
|
Corporate Author:
|
Parke-Davis
|
|
Search Terms in Context:
|
pgNbr=1
PARKE-DAVIS
1998 Marketing Plan
Neurontin
0 01 V
cn
to
UJ
pgNbr=2
PAFri(E-DAVIS
1998 Marketing Plan
Anti-convulsant Market
Class Sales History
1995 1996 1997 Est. 1998 Proj.
Audited Sales 886 1,131 1,462 1,686
($MM) +29.5% +29.3% +15.3%
TRxs 24,012 26,658 28,996
(000) + 8.9% +11.0% +8.8%
(Retail & Mail Order)
US/NEURONTIN 2
pgNbr=3
PARHEEDAVIS
1998 Marketing Plan
TRx Volume
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/ica00a10
|
|
| |
7.
Neurontin: Core Marketing Meeting, New York, 8-9 April 1997
|
Document Date:
|
19970328
|
|
Search Terms in Context:
|
Neuron tin
.t
Core Marketing Team Meeting
New York,. NY
8-9 April 1997
d:pplrw9kwndldw.ankn.pp*328197 P .1
pgNbr=1
INEURONTIN®
Market Summary
Clinical Update
-- Monotherapy
Pediatrics
Regulatory Update
Monotherapy
Pediatrics
Neuropathic Pain
New Formulations
Dosage vs Pricing
c) Competition
Marketing Needs Review
Current Uses
1997 Key Activities
Agenda
pgNbr=2
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/jdb00a10
|
|
| |
|
Prev
Next
|
